Anabelle Colaco
04 Sep 2025, 22:51 GMT+10
BAGSVÆRD, Denmark: Novo Nordisk said its weight-loss drug Wegovy sharply outperformed Eli Lilly's Mounjaro and Zepbound in reducing the risk of major heart problems in overweight and obese patients with cardiovascular disease.
In a real-world study of more than 21,000 patients, Wegovy users saw a 57 percent greater risk reduction for heart attack, stroke, and cardiovascular-related death compared with those on Lilly's drugs. Novo said the results strengthen evidence that the heart-protective benefits of its active ingredient semaglutide may not extend to all GLP-1 treatments, such as tirzepatide, used in Mounjaro and Zepbound.
The analysis, presented at the European Society of Cardiology meeting in Madrid, showed that just 15 Wegovy patients (0.1 percent) experienced a major adverse heart event compared with 39 tirzepatide patients (0.4 percent). Average follow-up was 3.8 months for Wegovy users and 4.3 months for tirzepatide users.
Across all patients, regardless of treatment gaps, Wegovy was linked to a 29 percent lower risk of heart events and death from any cause.
The findings come as Novo faces stiff competition from Lilly, which has been steadily gaining U.S. market share with Zepbound. Wegovy, approved in 2021, made Novo Europe's most valuable company, but in August, the drugmaker imposed a global hiring freeze on non-critical roles amid intensifying industry rivalry. Denmark also cut its 2025 economic growth forecast, citing weaker expectations for Novo's sales.
Both Wegovy and Zepbound dominate the rapidly expanding obesity market, which some analysts forecast will hit US$150 billion by the early 2030s. Wegovy also has an edge with late-stage trial data showing 15 percent weight loss in adults, and the U.S. Food and Drug Administration is reviewing a high-dose oral version for potential approval later this year.
Novo cautioned that real-world studies cannot prove cause and effect like randomized clinical trials, and noted the short follow-up as a limitation.
Get a daily dose of Broadcast Communications news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Broadcast Communications.
More InformationBAGSVÆRD, Denmark: Novo Nordisk said its weight-loss drug Wegovy sharply outperformed Eli Lilly's Mounjaro and Zepbound in reducing...
DALLAS, Texas: Southwest Airlines has become the first U.S. carrier to fly a jet equipped with a secondary cockpit barrier, a safety...
AUBURN HILLS, Michigan: Stellantis is pulling back more than 219,000 vehicles in the United States after regulators flagged a defect...
NEW YORK, New York - U.S. stocks had a volatile day Wednesday with the tech sector powering ahead, while the broader Dow Jones index...
MENLO PARK, California: WhatsApp has uncovered a new cyberespionage campaign that exploited vulnerabilities in both its platform and...
NEW YORK CITY. New York: A U.S. appeals court has delivered a significant blow to one of President Donald Trump's signature economic...
Kathmandu [Nepal], September 4 (ANI): The Government of Nepal on Thursday decided to block 26 social media platforms for operating...
Share article Print article The British Broadcasting Corporation (BBC) established its first radio transmitter sites in Africa...
(Photo credit: Andrew Nelles / The Tennessean / USA TODAY NETWORK via Imagn Images) The IndyCar series finished its 2025 season on...
(250903) -- BEIJING, Sept. 3, 2025 (Xinhua) -- People watch live broadcasting of a grand gathering to commemorate the 80th anniversary...
(Photo credit: Kirby Lee-Imagn Images) Fans of Friday night NFL games: savor the contest this week between the Kansas City Chiefs...
European Commission President Ursula von der Leyen was flying into Bulgaria when her planes GPS system was jammed in a suspected Russian...
